Gastroduodenal Ulceration Associated with Radioembolization for the Treatment of Hepatic Tumors: An Institutional Experience and Review of the Literature

Naymagon, Steven; Warner, Richard R.P.; Patel, Kalpesh; Harpaz, Noam; Macháč, Josef; Weintraub, Joshua; Kim, Michelle K.

doi:10.1007/s10620-010-1156-y

Cited by 89 publications

(42 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several observational cohort studies [4][5][6][7][8][9][10] as well as a few meta-analyses dealing with radioembolization for chemorefractory mCRC have been published, all of them demonstrating the relative safety of the radioembolization technique and the potential for better survival. However, only limited data on late toxicity of 90 Y in this patient population are available [11][12][13]. Additionally, little information is available about potential prognostic factors for prolonged survival.…”

mentioning

confidence: 99%

Yttrium-90 radioembolization for the treatment of chemorefractory colorectal liver metastases: Technical results, clinical outcome and factors potentially influencing survival

et al. 2015

View full text Add to dashboard Cite

90 Y radioembolization to treat chemorefractory colorectal liver metastases were identified. Demographic, laboratory, imaging and dosimetry data were collected. Post-treatment technical and clinical outcomes were analyzed as well as overall survival; finally several factors potentially influencing survival were analyzed. Results: In total 88 patients were selected for angiographic workup; 71 patients (81%) finally underwent catheter-directed 90 Y microsphere infusion into the hepatic artery 25 days (standard deviation 13 days) after angiographic workup. Median infused activity was 1809 MBq; 30-day toxicity included: fatigue (n ¼ 39; 55%), abdominal discomfort (n ¼ 33; 47%), nausea (n ¼ 5; 7%), fever (n ¼ 14; 20%), diarrhea (n ¼ 6; 9%), liver function abnormalities and elevated bilirubin (transient) (n ¼ 3; 4%). Gastric ulcer was found in five patients (7%). A late complication was radioembolization-induced portal hypertension (REIPH) in three patients (4%). Median time to progression in the liver was 4.4 months. Estimated survival at six and 12 months was 65% and 30%, respectively, with a 50% estimated survival after 8.0 months in this group of chemorefractory patients. Prognostic factors for worse survival were high preprocedural bilirubin, alkaline phosphatase and tumor volume levels. Conclusion:90 Y microsphere radioembolization for chemorefractory colorectal liver metastases has an acceptable safety profile with a 50% estimated survival after 8.0 months. Pretreatment high bilirubin, alkaline phosphatase and tumor volume levels were associated with early death.

show abstract

mentioning

confidence: 99%

Yttrium-90 radioembolization for the treatment of chemorefractory colorectal liver metastases: Technical results, clinical outcome and factors potentially influencing survival

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The side effect is usually mild and limited to fatigue and constitutional symptoms (104,105). Nonetheless significant side effects due to non-targeted radiation resulted in cholecystitis, gastrointestinal ulcers, and pneumonitis were reported (43,97,103,(106)(107)(108)(109).…”

Section: Results Of Transarterial Radioembolization (Tare)mentioning

confidence: 99%

Bridging and downstaging therapy in patients suffering from hepatocellular carcinoma waiting on the list of liver transplantation

She¹,

Cheung²

2016

Transl. Gastroenterol. Hepatol.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a common primary malignancy worldwide especially in the patients with the background of chronic liver disease. Liver transplantation (LT) is the only curative treatment effective for both malignancy as well as the cirrhosis and portal hypertension. Unfortunately, living donor is not always possible and the deceased graft is scarce. Neoadjuvant therapies, therefore, have been developed as a downstaging treatment to try to downstage the tumor within the transplant criteria, or as a bridging therapy to control the tumor growth in patients while waiting in the transplant list. This paper reviewed the common modalities used as bridging and downstaging therapies for patients suffering from HCC before undergoing LT.

show abstract

“…Compared with tace, tare is safe for use in patients with portal vein thrombosis 111 , and a small study (12 patients) implied its safety in those with lobar or segmental biliary tract obstruction and normal bilirubin levels 112,113 . However, nontargeted radiation can lead to "bystander organ injury" such as cholecystitis, gastrointestinal ulcers, and pneumonitis 106,[113][114][115][116][117][118][119] . For that reason, tare procedures must be preceded by angiographic and scintigraphic mapping studies to evaluate the presence of shunts that might allow the radiosphere particles to bypass the liver and reach other organs.…”

Section: 24mentioning

confidence: 99%

The Role of Interventional Radiology in the Management of Hepatocellular Carcinoma

Molla

Almenieir

Simoneau³

et al. 2014

Current Oncology

View full text Add to dashboard Cite

show abstract

Gastroduodenal Ulceration Associated with Radioembolization for the Treatment of Hepatic Tumors: An Institutional Experience and Review of the Literature

Cited by 89 publications

References 49 publications

Yttrium-90 radioembolization for the treatment of chemorefractory colorectal liver metastases: Technical results, clinical outcome and factors potentially influencing survival

Yttrium-90 radioembolization for the treatment of chemorefractory colorectal liver metastases: Technical results, clinical outcome and factors potentially influencing survival

Bridging and downstaging therapy in patients suffering from hepatocellular carcinoma waiting on the list of liver transplantation

The Role of Interventional Radiology in the Management of Hepatocellular Carcinoma

Contact Info

Product

Resources

About